Introduction to biomaterials for cancer therapeutics

Biomaterials for Cancer Therapeutics: Diagnosis, Prevention and Therapy

Volumn , Issue , 2013, Pages 3-19

  Lee, B K ^a   Yun, Y H ^a   Park, K ^a   Sturek, M ^b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomaterials; Excipients; Nanovehicles; Polymers; Poorly soluble drugs

Indexed keywords

BIOMATERIALS; CELLS; CONTROLLED DRUG DELIVERY; DISEASES; DRUG INTERACTIONS; LIPOSOMES; POLYMERS; TUMORS;

ANTI-CANCER AGENTS; CANCER THERAPEUTICS; ENVIRONMENTAL CHANGE; EXCIPIENTS; NANOVEHICLES; POLYMERIC DELIVERY SYSTEMS; POORLY SOLUBLE DRUGS; WATER SOLUBILITIES;

TARGETED DRUG DELIVERY;

EID: 84902413815     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9780857096760.1.3     Document Type: Chapter

References (103)

1. Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Madden T.D., Bally M.B. The liposomal formulation of doxorubicin. Method Enzymol 2005, 391:71-96.
2. Accardo A., Tesauro D., Morelli G. Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors. Polym J 2013, 19:1-13.
3. Acharya S., Sahoo S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011, 63(3):170-183.
4. Agarwal A., Mackey M.A., El-Sayed M.A., Bellamkonda R.V. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano 2011, 5(6):4919-4926.
5. Ali O.A., Mooney D.J. Immunologically active biomaterials for cancer therapy. Curr Top Microbiol Immunol 2011, 344:279-297.
6. a determination of water-insoluble drugs in organic solvent-water mixtures. J Pharm Biomed Anal 1999, 20(4):631-641.
7. Bae Y.H., Park K. Targeted drug delivery to tumors: Myths, reality, and possibility. J Control Release 2011, 153:198-205.
8. Barenholz Y. Doxil® - The first FDA-approved nano-drug: Lessons learned. J. Control Release 2012, 160(2):117-134.
9. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60(15):1615-1626.
10. Chen H., Kim S., He W., Wang H., Low P.S., Park K., Cheng J.X. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo förster resonance energy transfer imaging. Langmuir 2008, 24:5213-5217.
11. Chen H., Kim S., Li L., Wang S., Park K., Cheng J.X. Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Förster resonance energy transfer imaging. Proc Natl Acad Sci USA 2008, 105:6596-6601.
12. Choi J.S., Yang H.J., Kim B.S., Kim J.D., Kim J.Y., Yoo B., Park K., Lee H.Y., Cho Y.W. Human extracellular matrix (ECM) powders for injectable cell delivery and adipose tissue engineering. J Control Release 2009, 139(1):2-7.
13. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012, 161(2):505-522.
14. Danhier F., Ucakar B., Magotteaux N., Brewster M.E., Préat V. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor. Int J Pharm 2010, 392(1-2):20-28.
15. DeNardo G.L., DeNardo S.J. Concepts, consequences, and implications of theranosis. Sem Nucl Med 2012, 42(3):147-150.
16. Deng J., Huang L., Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm 2010, 390(2):242-249.
17. Duncan B., Kim C., Rotello V.M. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release 2010, 148(1):122-127.
18. Elias D.R., Poloukhtine A., Popik V., Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine 2013, 9(2):194-201.
19. Fang C., Kievit F.M., Veiseh O., Stephen Z.R., Wang T., Lee D., Ellenbogen R.G., Zhang M. Fabrication of magnetic nanoparticles with controllable drug loading and release through a simple assembly approach. J Control Release 2012, 162(1):233-241.
20. Felber A.E., Dufresne M.-H., Leroux J.-C. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Deliv Rev 2012, 64(11):979-992.
21. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., Mooney D.J. Engineering tumors with 3D scaffolds. Nat Methods 2007, 4(10):855-860.
22. Gao L., Liu G., Ma J., Wang X., Zhou L., Li X. Drug nanocrystals: In vivo performances. J Control Release 2012, 160(3):418-430.
23. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963, 105(5):574-578.
24. Godugu C., Patel A.R., Desai U., Andey T., Sams A., Singh M. Algimatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One 2013, 8(1):1-13.
25. Goutayer M., Dufort S., Josserand V., Royère A., Heinrich E., Vinet F., Bibette J., Coll J.L., Texier I. Tumor targeting of functionalized lipid nanoparticles: Assessment by in-vivo fluorescence imaging. Eur J Pharm Biopharm 2010, 75(2):137-147.
26. Grama C.N., Ankola D.D., Kumar M.N.V.R. Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives. Curr Opin Colloid Interface Sci 2011, 16(3):238-245.
27. Hamaguchi T., Matsumura Y., Suzuki M., Shimizu K., Goda R., Nakamura I., Nakatomi I., Yokoyama M., Kataoka K., Kakizoe T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005, 92:1240-1246.
28. Hecq J., Deleers M., Fanara D., Vranckx H., Boulanger P., Le Lamer S., Amighi K. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 2006, 64(3):360-368.
29. Deeley T.J. A brief history of cancer. Clin Radiol 1983, 34:597-608.
30. James N.D., Coker R.J., Tomlinson D., Harris J.R., Gompels M., Pinching A.J., Stewart J.S. Liposomal doxorubicin (doxil): An effective new treatment for kaposi's sarcoma in AIDS. Clin Oncol 1994, 6:294-296.
31. Kang S.I., Na K., Bae Y.H. Physicochemical characteristics and doxorubicin-release behaviors of pH/temperature-sensitive polymeric nanoparticles. Colloids Surf A Physicochem Eng Asp 2003, 231(1-3):103-112.
32. Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., Ruoslahti E. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5(1):73-82.
33. Kim D., Jon S. Gold nanoparticles in image-guided cancer therapy. Inorganica Chim Acta 2012, 393:154-164.
34. Kim J.B. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005, 15(5):365-377.
35. Kim J.Y., Kim S., Papp M., Park K., Pinal R. Hydrotropic solubilization of poorly water-soluble drugs. J Pharm Sci 2010, 99(9):3953-3965.
36. Kim K., Kim J.H., Park H., Kim Y.S., Park K., Nam H., Lee S., Park J.H., Park R.W., Kim I.S., Choi K., Kim S.Y., Park K., Kwon I.C. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 2010, 146(2):219-227.
37. Kim S., Kim J.Y., Huh K.M., Acharya G., Park K. Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J Control Release 2008, 132(3):222-229.
38. Kim T., Doh I., Cho Y.-H. A 3D tumor spheroid chip with the pharmaco-kinetic drug elimination model developed by balanced droplet dispensing. Sens Actuators B Chem 2012, 174:436-440.
39. Klein S., Levitzki A. Targeted cancer therapy: Promise and reality. Advances in Cancer Research 2007, 295-319. Academic Press. F.V.W. George, K. George (Eds.).
40. Kleinman H.K., Martin G.R. Matrigel: Basement membrane matrix with biological activity. Semin Cancer Biol 2005, 15:378-386.
41. Klostergaard J., Seeney C.E. Magnetic nanovectors for drug delivery. Nanomedicine 2012, 8(1):S37-S50.
42. Kono K., Ozawa T., Yoshida T., Ozaki F., Ishizaka Y., Maruyama K., Kojima C., Harada A., Aoshima S. Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy. Biomaterials 2010, 31(27):7096-7105.
43. Kost J., Langer R. Responsive polymeric delivery systems. Adv Drug Deliv Rev 2012, 64:327-341. Supplement.
44. Lan S.-F., Starly B. Alginate based 3D hydrogels as an in vitro co-culture model platform for the toxicity screening of new chemical entities. Toxicol Appl Pharmacol 2011, 256(1):62-72.
45. Lee S.C., Huh K.M., Lee J., Cho Y.W., Galinsky R.E., Park K. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: In vitro and in vivo characterization. Biomacromolecules 2007, 8(1):202-208.
46. Li L., ten Hagen T.L., Bolkestein M., Gasselhuber A., Yatvin J., van Rhoon G.C., Eggermont A.M., Haemmerich D., Koning G.A. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J Control Release 2013, 167(2):130-137.
47. Loos W.J., Baker S.D., Verweij J., Boonstra J.G., Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003, 74(4):364-371.
48. Lu J., Owen S.C., Shoichet M.S. Stability of self-assembled polymeric micelles in serum. Macromolecules 2011, 44:6002-6008.
49. Lukyanov A.N., Torchilin V.P. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004, 56(9):1273-1289.
50. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71(3):409-419.
51. Mahon E., Salvati A., Baldelli Bombelli F., Lynch I., Dawson K.A. Designing the nanoparticle - biomolecule interface for ' targeting and therapeutic delivery'. J Control Release 2012, 161(2):164-174.
52. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
53. Miller T., Breyer S., van Colen G., Mier W., Haberkorn U., Geissler S., Voss S., Weigandt M., Goepferich A. Premature drug release of polymeric micelles and its effects on tumor targeting. Int J Pharm 2013, 445(1-2):117-124.
54. Miller T., Rachel R., Besheer A., Uezguen S., Weigandt M., Goepferich A. Comparative investigations on in vitro serum stability of polymeric micelle formulations. Pharm Res 2012, 29:448-459.
55. Modi S., Xiang T.-X., Anderson B.D. Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions. J Control Release 2012, 162(2):330-339.
56. Mohammed A.R., Weston N., Coombes A.G., Fitzgerald M., Perrie Y. Liposome formulation of poorly water soluble drugs: Optimisation of drug loading and ESEM analysis of stability. Int J Pharm 2004, 285(1-2):23-34.
57. Muller R.H., Keck C.M. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanopar-ticles. J Biotechnol 2004, 113(1-3):151-170.
58. Müller R.H., Keck C.M. Twenty years of drug nanocrystals: Where are we, and where do we go?. Eur J Pharm Biopharm 2012, 80:1-3.
59. Müllertz A., Ogbonna A., Ren S., Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharm 2010, 62:1622-1636.
60. Nichols J.W., Bae Y.H. Odyssey of a cancer nanoparticle: From injection site to site of action. Nano Today 2012, 7(6):606-618.
61. Oh K.S., Han S.K., Choi Y.W., Lee J.H., Lee J.Y., Yuk S.H. Hydrogen-bonded polymer gel and its application as a temperature-sensitive drug delivery system. Biomaterials 2004, 25(12):2393-2398.
62. Park J., Fong P.M., Lu J., Russell K.S., Booth C.J., Saltzman W.M., Fahmy T.M. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 2009, 5(4):410-418.
63. Park J.H., Saravanakumar G., Kim K., Kwon I.C. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev 2010, 62(1):28-41.
64. Pasut G., Veronese F.M. State of the art in PEGylation: The great versatility achieved after forty years of research. J Control Release 2012, 161(2):461-472.
65. Pohlmann A.R., Mezzalira G., Venturini C., de G., Cruz L., Bernardi A., Jäger E., Battastini A.M., da Silveira N.P., Guterres S.S. Determining the simultaneous presence of drug nanocrystals in drug-loaded polymeric nanocapsule aqueous suspensions: A relation between light scattering and drug content. Int J Pharm 2008, 359(1-2):288-293.
66. Qiu Y., Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2012, 64:49-60. Supplement.
67. Rahman A.M., Yusuf S.W., Ewer M.S. Anthracycline-induced car-diotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine 2007, 2(4):567-583.
68. Saad M., Garbuzenko O.B., Ber E., Chandna P., Khandare J.J., Pozharov V.P., Minko T. Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging?. J Control Release 2008, 130(2):107-114.
69. Shao J., Griffin R.J., Galanzha E.I., Kim J.W., Koonce N., Webber J., Mustafa T., Biris A.S., Nedosekin D.A., Zharov V.P. Photothermal nanodrugs: Potential of TNF-gold nanospheres for cancer theranostics. Sci Rep 2013, 3(1293):1-9.
70. Sharma A., Sharma U.S. Liposomes in drug delivery: Progress and limitations. Int J Pharm 1997, 154(2):123-140.
71. Shin C.S., Kwak B., Han B., Park K. Development of an in vitro 3D tumor model to study therapeutic efficiency of an anti-cancer drug. Mol Pharm 2013, 10(6):2167-2175.
72. Simamora P., Alvarez J.M., Yalkowsky S.H. Solubilization of rapamycin. Int J Pharm 2001, 213(1-2):25-29.
73. Singh R., Lillard J.W. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009, 86(3):215-223.
74. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235(1-2):179-192.
75. Sinha S., Ali M., Baboota S., Ahuja A., Kumar A., Ali J. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. PharmSci Tech 2010, 11(2):518-527.
76. Sodunke T.R., Turner K.K., Caldwell S.A., McBride K.W., Reginato M.J., Noh H.M. Micropatterns of matrigel for three-dimensional epithelial cultures. Biomaterials 2007, 28(27):4006-4016.
77. Sparreboom A., van Zuylen L., Brouwer E., Loos W.J., de Bruijn P., Gelderblom H., Pillay M., Nooter K., Stoter G., Verweij J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 1999, 59:1454-1457.
78. Studenovsky M., Pola R., Pechar M., Etrych T., Ulbrich K., Kovar L., Kabesova M., Rihova B. Polymer carriers for anticancer drugs targeted to EGF receptor. Macromol Biosci 2012, 12:1714-1720.
79. Talukdar S., Kundu S.C. A non-mulberry silk fibroin protein based 3D in vitro tumor model for evaluation of anticancer drug activity. Adv Funct Mater 2012, 22:4778-4788.
80. Terreno E., Uggeri F., Aime S. Image guided therapy: The advent of theranostic agents. J Control Release 2012, 161(2):328-337.
81. Tinkov S., Coester C., Serba S., Geis N.A., Katus H.A., Winter G., Bekeredjian R. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: In-vivo characterization. J Control Release 2010, 148(3):368-372.
82. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63(3):131-135.
83. Torisawa Y.-S., Shiku H., Yasukawa T., Nishizawa M., Matsue T. Multichannel 3-D cell culture device integrated on a silicon chip for anticancer drug sensitivity test. Biomaterials 2005, 26(14):2165-2172.
84. Torosean S., Flynn B., Axelsson J., Gunn J., Samkoe K.S., Hasan T., Doyley M.M., Pogue B.W. Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. Nanomedicine 2013, 9:151-158.
85. Tran V.-T., Karam J.P., Garric X., Coudane J., Benoît J.P., Montero-Menei C.N., Venier-Julienne M.C. Protein-loaded PLGA-PEG-PLGA microspheres: A tool for cell therapy. Eur J Pharm Sci 2012, 45(1-2):128-137.
86. van der Laan J.W., Brightwell J., McAnulty P., Ratky J., Stark C., Steering Group of the RETHINK Project Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. J Pharmacol Toxicol Methods 2010, 62:184-195.
87. Wang A., Gao H., Sun Y., Sun Y.L., Yang Y.W., Wu G., Wang Y., Fan Y., Ma J. Temperature- and pH-responsive nanoparticles of biocompatible polyurethanes for doxorubicin delivery. Int J Pharm 2013, 441:30-39.
88. Wang G.D., Mallet F.P., Ricard F., Heng J.Y. Pharmaceutical nanocrystals. Curr Opin Chem Eng 2012, 1(2):102-107.
89. Wang H., Zhao Y., Wu Y., Hu Y.L., Nan K., Nie G., Chen H. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32(32):8281-8290.
90. Wang Z., Yu Y., Dai W., Cui J., Wu H., Yuan L., Zhang H., Wang X., Wang J., Zhang X., Zhang Q. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth. Biomaterials 2013, 34(3):756-764.
91. Winau F., Westphal O., Winau R. Paul Ehrlich - in search of the magic bullet. Microbes Infect 2004, 6(8):786-789.
92. Wlodkowic D., Cooper J.M. Tumors on chips: Oncology meets microfluidics. Curr Opin Chem Biol 2010, 14(5):556-567.
93. Won Y.Y., Sharma R., Konieczny S.F. Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes. J Control Release 2009, 139(2):88-93.
94. Wu M.-H., Chang Y.-H., Liu Y.-T., Chen Y.-M., Wang S.-S., Wang H.-Y., Lai C.-S., Pan T.-M. Development of high throughput microfluidic cell culture chip for perfusion 3-dimensional cell culture-based chemosensitivity assay. Sens Actuators B Chem 2011, 155(1):397-407.
95. Xie J., Lee S., Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010, 62(11):1064-1079.
96. Xu X., Gurski L.A., Zhang C., Harrington D.A., Farach-Carson M.C., Jia X. Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids. Biomaterials 2012, 33(35):9049-9060.
97. Yoshii Y., Waki A., Yoshida K., Kakezuka A., Kobayashi M., Namiki H., Kuroda Y., Kiyono Y., Yoshii H., Furukawa T., Asai T., Okazawa H., Gelovani J.G., Fujibayashi Y. The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. Biomaterials 2011, 32(26):6052-6058.
98. Zhang H., Hollis C.P., Zhang Q., Li T. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm 2011, 415(1-2):293-300.
99. Zhang J., Lv H., Jiang K., Gao Y. Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. Int J Pharm 2011, 420(1):180-188.
100. Zhang Y., Chan H.F., Leong K.W. Advanced materials and processing for drug delivery: The past and the future. Adv Drug Deliv Rev 2013, 65(1):104-120.
101. Zhao R., Hollis C.P., Zhang H., Sun L., Gemeinhart R.A., Li T. Hybrid nanocrystals: Achieving concurrent therapeutic and bioimaging functionalities toward solid tumors. Mol Pharmaceut 2011, 8:1985-1991.
102. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., Pei Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: The effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31(6):1360-1371.
103. Ziólkowska K., Stelmachowska A., Kwapiszewski R., Chudy M., Dybko A., Brzozka Z. Long-term three-dimensional cell culture and anticancer drug activity evaluation in a microfluidic chip. Biosens Bioelectron 2013, 40:68-74.